Kringle Pharma, Inc. (4884) AI Stock Analysis

• Market Cap: ¥2.90B
• Dividend Yield: N/A
• Average Volume (3M): 51.60K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.03
• Revenue Growth: -9.77%
• EPS Growth: -13.86%
• Country: JP
• Employees: 15
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -28.20
• Shares Outstanding: 7,349,200
• 10 Day Avg. Volume: 53,170
• 30 Day Avg. Volume: 51,600
• PEG Ratio: -0.26
• Price to Book (P/B): 2.41
• Price to Sales (P/S): 43.77
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: ¥370.00 ▼(-2.37% Downside)
• Action: Reiterated Date: 12/30/25
• Date: Action: Reiterated 12/30/25

The score is driven primarily by weak financial performance (volatile and contracting revenue, large losses, and heavy cash burn) despite the benefit of zero debt. Technicals add pressure with a downtrend versus key moving averages and negative MACD. Valuation provides limited support due to negative earnings and no dividend yield data.

Positive Factors

Global Expansion

The establishment of a U.S. subsidiary expands Kringle Pharma's global footprint, potentially accelerating development and commercialization in a key market, enhancing long-term growth prospects.

Regulatory Advantage

The orphan drug designation provides regulatory benefits, including market exclusivity, which can enhance the competitive position and profitability of Kringle Pharma's products.

Debt-Free Balance Sheet

A debt-free balance sheet reduces financial risk, providing Kringle Pharma with greater flexibility to invest in R&D and strategic initiatives without the burden of interest obligations.

Negative Factors

Cash Flow Challenges

Persistent negative cash flow indicates significant cash burn, which may necessitate additional funding and could strain financial resources, impacting long-term sustainability.

Declining Equity

The decline in equity reflects sustained losses, eroding the capital base and potentially limiting the company's ability to invest in growth opportunities without external financing.

Revenue Volatility

Volatile and contracting revenue suggests instability in the business model, which can hinder strategic planning and long-term growth, affecting investor confidence and operational stability.

Kringle Pharma, Inc. Business Overview & Revenue Model

Company Description

Kringle Pharma, Inc. engages in the research and development, manufactures, and sells hepatocyte growth factor (HGF) protein pharmaceuticals for regenerative medicines. The company develops HGF products for the treatment of acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scar, and acute kidney injury. Kringle Pharma, Inc. was incorporated in 2001 and is based in Ibaraki, Japan.

How the Company Makes Money

Kringle Pharma, Inc. generates revenue through the development and commercialization of its proprietary therapeutic products. The company primarily earns money by advancing its drug candidates through clinical trials and subsequently licensing these products to pharmaceutical companies. Revenue streams include milestone payments from partnerships, licensing agreements, and potential royalties from product sales once the therapies reach the market. Strategic collaborations with other biotech and pharma companies also play a significant role in funding its research and development efforts, contributing to its earnings.

Kringle Pharma, Inc. Financial Statement Overview

Summary

Low leverage with zero debt supports the balance sheet, but operating fundamentals are weak: revenue is volatile and recently contracted (~25% in 2025 vs. 2024), losses remain large relative to sales, equity has been eroded by sustained losses, and cash burn is significant with strongly negative operating cash flow in 2024–2025.

Income Statement

Revenue is volatile and has recently contracted (down ~25% in 2025 vs. 2024 after prior swings), while profitability remains deeply negative. Net losses are large relative to sales (net margin ~-13% in 2025 and ~-9% in 2024), indicating the business is still far from operating leverage; gross profit data is also inconsistent year-to-year (including a 0 gross profit reading in 2025), adding uncertainty to the underlying margin picture. The main strength is that revenue continues to exist at a meaningful level for a development-stage biotech, but the scale of ongoing losses is the dominant issue.

Balance Sheet

The balance sheet is conservatively levered with zero debt across the periods shown, which materially reduces financial risk. However, equity has declined notably from prior years (e.g., from ~2.8B in 2022 to ~1.3B in 2025), reflecting sustained losses, and returns on equity are sharply negative (about -70% in 2025). Overall, low leverage is a clear positive, but continuing losses are eroding the capital base.

Cash Flow

Cash generation is weak, with operating cash flow negative in most years and strongly negative in the last two periods (about -756M in 2025 and -661M in 2024), consistent with heavy cash burn. The only bright spot is that 2022 showed modest positive operating and free cash flow, but it was not sustained, and the cash flow profile reverted to sizeable outflows thereafter. This raises ongoing funding risk despite the lack of debt.

Breakdown	Sep 2025	Sep 2024	Sep 2023	Sep 2022	Sep 2021
Income Statement
Total Revenue	72.22M	80.04M	69.25M	391.83M	289.76M
Gross Profit	72.22M	80.04M	69.25M	303.42M	218.16M
EBITDA	-914.76M	-817.88M	-888.76M	-426.17M	-357.88M
Net Income	-916.25M	-756.45M	-854.15M	-331.83M	-301.17M
Balance Sheet
Total Assets	2.08B	2.76B	2.62B	3.21B	2.64B
Cash, Cash Equivalents and Short-Term Investments	1.62B	2.31B	2.14B	2.76B	2.14B
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Liabilities	770.11M	648.92M	596.95M	419.50M	129.48M
Stockholders Equity	1.31B	2.11B	2.02B	2.79B	2.51B
Cash Flow
Free Cash Flow	0.00	-661.17M	-689.10M	15.80M	-560.92M
Operating Cash Flow	-755.78M	-661.17M	-689.10M	15.80M	-560.92M
Investing Cash Flow	-154.01M	-121.36M	-120.88M	-254.38M	0.00
Financing Cash Flow	84.14M	838.23M	69.16M	603.11M	595.90M

Kringle Pharma, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 379.00
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4884, the sentiment is Positive. The current price of 379 is below the 20-day moving average (MA) of 383.45, below the 50-day MA of 390.62, and below the 200-day MA of 538.40, indicating a neutral trend. The MACD of -1.88 indicates Negative momentum. The RSI at 54.82 is Neutral, neither overbought nor oversold. The STOCH value of 62.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4884.

Kringle Pharma, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4571	52 Neutral	¥14.02B	-14.93	-26.70%	―	172.39%	8.27%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4881	48 Neutral	¥4.06B	-1.96	―	―	-16.23%	-51.84%
4587	46 Neutral	¥185.07B	-49.16	-10.16%	―	-62.47%	-134.06%
4591	43 Neutral	¥4.67B	-3.88	―	―	-100.00%	7.60%
4884	42 Neutral	¥2.90B	-3.02	―	―	-9.77%	-13.86%
4598	39 Underperform	¥3.30B	-1.66	―	―	―	25.25%

Kringle Pharma, Inc. Corporate Events

Kringle Pharma Posts Narrower Quarterly Loss but Confirms Deep Full-Year Deficit Forecast

Kringle Pharma reported net sales of ¥18 million for the three months ended December 31, 2025, flat year on year, while operating and ordinary losses narrowed slightly to around ¥199–¥200 million, resulting in a quarterly net loss of ¥201 million and a basic loss per share of ¥28.20. Total assets declined to ¥1,990 million and the equity ratio edged down to 59.7%, the company maintained a zero-dividend policy, and it reaffirmed its full-year forecast for flat sales of ¥72 million alongside a significantly larger projected loss of about ¥1.17 billion, underscoring ongoing heavy investment and sustained financial pressure into fiscal 2026.

Kringle Pharma’s financial position softened slightly this quarter as net assets decreased to ¥1,220 million, reflecting continued losses despite stable top-line performance. With no revisions to its earnings or dividend outlook and no change in accounting policies, the company signals operational and strategic continuity, but the projected deep full-year loss highlights persistent profitability challenges for investors and other stakeholders.

The most recent analyst rating on (JP:4884) stock is a Hold with a Yen359.00 price target. To see the full list of analyst forecasts on Kringle Pharma, Inc. stock, see the JP:4884 Stock Forecast page.